Eli Lilly Reports Retatrutide Reduced Knee Osteoarthritis Pain in Phase 3 Study
Eli Lilly reported that retatrutide reduced knee osteoarthritis pain in a Phase 3 study.
Related stories
Core Natural Resources Reports Third-Quarter 2026 Results
Core Natural Resources reported third-quarter 2026 results.
M impact | EQUITY | Nov 05, 2026, 12:05 PM UTC
Global Payments Q3 Adjusted Revenue $3.180B vs. IBES Estimate $3.182B
M impact | EQUITY | Nov 05, 2026, 11:55 AM UTC
Iron Mountain reports Q3 earnings
Iron Mountain Inc. (IRM) reported earnings, according to the Associated Press.
M impact | EQUITY | Nov 05, 2026, 11:55 AM UTC
Novonesis CEO Says Weak US Sentiment Weighs on Supplement Sales
The CEO said changing US consumer behavior and weaker buying power are weighing on the North American dietary supplement market. Novonesis expects the market to return to growth on
L impact | EQUITY | Nov 05, 2026, 11:55 AM UTC
Bob’s Discount Furniture Reports Third-Quarter 2026 Results
Bob’s Discount Furniture announced results for the fiscal quarter ended September 27, 2026. The company said it delivered sales growth, market-share gains and margin expansion.
M impact | EQUITY | Nov 05, 2026, 11:55 AM UTC
GEO Group Reports Q3 Results and Updates 2026 Guidance
Third-quarter 2026 revenue rose 12% to $761.1 million. The company also updated its full-year 2026 guidance.
M impact | EQUITY | Nov 05, 2026, 11:55 AM UTC